Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Weill Cornell College, New York

1 abstract

Abstract
A RANDOMIZED DOUBLE-BLIND TREATMENT STRATEGY STUDY EVALUATING CONTINUATION OR REDUCED-FREQUENCY DOSING OF CERTOLIZUMAB PEGOL VERSUS WITHDRAWAL TO MAINTAIN LOW DISEASE ACTIVITY IN EARLY RA PATIENTS (C-EARLY PERIOD 2)
Org: Weill Cornell College, New York, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, UCB Pharma, Raleigh, United States, UCB Pharma, Brussels, Belgium,